Table 1.
Baseline Characteristics of Patients
| Variable | Value (n=54) |
|---|---|
| Demographic and clinical characteristics | |
| Age at CRT implantation, y | 46±13 |
| Men | 40 (74) |
| Follow‐up duration, y | 5.7±3.0 |
| SBP at CRT implantation, mmHg | 112±15 |
| DBP at CRT implantation, mmHg | 70±10 |
| BMI, kg/m2 | 25.7 (22.9–29.7) |
| Biochemical parameters | |
| Urea, mmol/L | 7.1 (5.2–7.9) |
| Creatinine, μmol/L | 84 (76–94) |
| ECG | |
| Sinus rhythm | 44 (81) |
| Atrial fibrillation | 10 (19) |
| QRS duration, ms | 174±27 |
| QRS morphological characteristics | |
| LBBB | 15 (28) |
| Non‐LBBB | 39 (72) |
| Device implantation | |
| PPM/ICD upgrade to CRT | 31 (57) |
| CRT de novo | 23 (43) |
| CRTD | 46 (85) |
| CRTP | 8 (15) |
| NYHA functional class | |
| I | 3 (6) |
| II | 20 (37) |
| III | 28 (51) |
| IV | 3 (6) |
| Drug treatment | |
| ACEI or ARB | 52 (96) |
| β Blocker | 48 (89) |
| Aldosterone antagonist | 35 (65) |
| Loop diuretic | 28 (52) |
| Amiodarone | 11 (20) |
| Anticoagulation | 36 (67) |
| Digoxin | 5 (9) |
| Device‐related complications | |
| Infection | 5 (9) |
| Lead dislodgement | 3 (6) |
| Venous obstruction | 1 (2) |
| Pneumohemothorax and pulmonary embolism | 1 (2) |
Values are mean±SD, median (interquartile range), or number (percentage). ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; CRTD, CRT‐implantable cardioverter‐defibrillator; CRTP, CRT pacemaker; DBP, diastolic blood pressure; ICD, implantable cardioverter‐defibrillator; LBBB, left bundle branch block; NYHA, New York Heart Association; PPM, permanent pacemaker; SBP, systolic blood pressure.